Go Pro
NASDAQ:GHRS

GH Research Q4 2024 Earnings Report

GH Research logo
$25.96 -1.90 (-6.82%)
Closing price 09/23/2026 04:00 PM Eastern
Extended Trading
$25.58 -0.38 (-1.48%)
As of 06:33 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

GH Research EPS Results

Actual EPS
-$0.17
Consensus EPS
-$0.23
Beat/Miss
Beat by +$0.06
One Year Ago EPS
N/A

GH Research Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

GH Research Announcement Details

Quarter
Q4 2024
Time
Before Market Opens
Conference Call Date
Thursday, February 27, 2025
Conference Call Time
9:30AM ET

Upcoming Earnings

GH Research's Q3 2026 earnings is estimated for Thursday, November 5, 2026, based on past reporting schedules, with a conference call scheduled on Friday, November 6, 2026 at 12:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

GH Research Earnings Headlines

While SpaceX Gets the Spotlight, FJET Is Building What Comes Next!
Starfighters Space (NYSE: FJET) operates the world's only commercial fleet of flight-ready Mach 2+ F-104 Starfighter aircraft, giving it a rare platform for high-speed flight testing, captive-carry missions and aerospace research. Its Wind Tunnel in the Sky concept exposes hardware to real high-speed atmospheric conditions, while new collaborations with Vaya Defense & Space and The Bionetics Corporation expand its reach into propulsion, hypersonic test articles and payload processing. FJET is also developing STARLAUNCH, an air-launched system targeting suborbital missions, positioning the company across testing, defense and launch.tc pixel
See More GH Research Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like GH Research? Sign up for Earnings360's daily newsletter to receive timely earnings updates on GH Research and other key companies, straight to your email.

About GH Research

GH Research (NASDAQ:GHRS) is a clinical-stage biopharmaceutical company headquartered in Dublin, Ireland. Founded in 2018, the company focuses on developing novel therapies for psychiatric and neurological disorders, with an emphasis on treatments that may offer rapid effects.

Its lead program, GH001, is an inhaled formulation of mebufotenin, also known as 5-MeO-DMT, being studied for treatment-resistant depression. GH Research is also developing additional formulations and delivery approaches based on mebufotenin, including the GH002 program. The company’s pipeline remains in clinical development, and it does not currently have marketed products.

GH Research conducts its research and clinical development activities internationally, including in the United States and Europe. The company’s programs are intended for patients with significant unmet needs in psychiatric medicine, subject to the results of clinical trials and regulatory review.

View GH Research Profile